FMTX

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for patients with rare hematologic diseases and cancers. Its pipeline consists of seven product candidates, two of which it is pursuing as core product candidates for development: FT-4202 for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Its other product candidate includes FT-2102 (Olutasidenib), FT-8225, FT-4101, CC-95775 and BI-1701963. FT-4202 is an oral, once-daily, potentially disease-modifying therapy. FT-4202 is a potent activator of pyruvate kinase-R (PKR), designed to improve RBC metabolism, function and survival, and potentially resulting in both increased hemoglobin levels and reduced VOCs. FT-7051, is a potent and selective inhibitor of CREB-binding protein/E1A binding protein p300 (CBP/p300).